Horizon 2


A Randomized, Observer-blind, Phase 2/3 Adaptive Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a One- or Two-dose Regimen in Healthy Adolescents From 12 to 17 Years Inclusive.


This study will use young adults from VAC31518COV3001 and VAC31518COV3009 as external controls and therefore will only enroll participants who are 12 to 17 years of age.


  • Prof Lee Fairlie (Principal Investigator)
  • Dr Faeezah Patel
  • Dr Elizea Horne
  • Tiffany Seef
  • Othusiste Segalo
  • Dr Mrinmayee Dhar

Latest Update

September 2023

For more about PrEP SMART please email

Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.